Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-11-22

AUTHORS

Yong Yook Lee, Hwang-Phill Kim, Min Jueng Kang, Byoung-Kyu Cho, Sae-Won Han, Tae-You Kim, Eugene C Yi

ABSTRACT

Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro. However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge. To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer. Biological network analysis of differentially expressed phosphoproteins revealed apparent constitutive activation of the MET-axis phosphatidylinositide 3-kinase (PI3K)/α-serine/threonine-protein kinase (AKT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways in SNU216-LR. Inhibition of the PI3K/AKT and MAPK/ERK signaling pathways in SNU216-LR also leads to cell cycle arrest, confirming the biological network analysis. Lapatinib sensitivity was restored when cells were treated with several molecular targeting agents in combination with lapatinib. Thus, by integrating phosphoproteomic data, protein networks and effects of signaling pathway modulation on cell proliferation, we found that SNU216-LR maintains constitutive activation of the PI3K/AKT and MAPK/ERK pathways in a MET-dependent manner. These findings suggest that pathway activation is a key compensatory intracellular phospho-signaling event that may govern gastric cancer cell resistance to drug treatment. More... »

PAGES

e64-e64

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/emm.2013.115

DOI

http://dx.doi.org/10.1038/emm.2013.115

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025899051

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24263233


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medicinal and Biomolecular Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lapatinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Signaling System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinase Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphatidylinositol 3-Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteomics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-met", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea", 
            "Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Yong Yook", 
        "id": "sg:person.01007741370.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007741370.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Institute, Seoul National University, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Cancer Research Institute, Seoul National University, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Hwang-Phill", 
        "id": "sg:person.01061620023.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061620023.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Min Jueng", 
        "id": "sg:person.01170702676.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170702676.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cho", 
        "givenName": "Byoung-Kyu", 
        "id": "sg:person.0726657204.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726657204.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "Sae-Won", 
        "id": "sg:person.0626600563.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626600563.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Cancer Research Institute, Seoul National University, Seoul, Republic of Korea", 
            "Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Tae-You", 
        "id": "sg:person.012010335604.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012010335604.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea", 
            "Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yi", 
        "givenName": "Eugene C", 
        "id": "sg:person.01064603366.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064603366.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ncponc1156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031325623", 
          "https://doi.org/10.1038/ncponc1156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2011.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017010571", 
          "https://doi.org/10.1038/onc.2011.84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt1240", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011188595", 
          "https://doi.org/10.1038/nbt1240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2011.130", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047704859", 
          "https://doi.org/10.1038/onc.2011.130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604937", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051636968", 
          "https://doi.org/10.1038/sj.bjc.6604937"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-11-22", 
    "datePublishedReg": "2013-11-22", 
    "description": "Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro. However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge. To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer. Biological network analysis of differentially expressed phosphoproteins revealed apparent constitutive activation of the MET-axis phosphatidylinositide 3-kinase (PI3K)/\u03b1-serine/threonine-protein kinase (AKT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways in SNU216-LR. Inhibition of the PI3K/AKT and MAPK/ERK signaling pathways in SNU216-LR also leads to cell cycle arrest, confirming the biological network analysis. Lapatinib sensitivity was restored when cells were treated with several molecular targeting agents in combination with lapatinib. Thus, by integrating phosphoproteomic data, protein networks and effects of signaling pathway modulation on cell proliferation, we found that SNU216-LR maintains constitutive activation of the PI3K/AKT and MAPK/ERK pathways in a MET-dependent manner. These findings suggest that pathway activation is a key compensatory intracellular phospho-signaling event that may govern gastric cancer cell resistance to drug treatment.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/emm.2013.115", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1085098", 
        "issn": [
          "1226-3613", 
          "2092-6413"
        ], 
        "name": "Experimental & Molecular Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "45"
      }
    ], 
    "keywords": [
      "mitogen-activated protein kinase", 
      "epidermal growth factor receptor", 
      "PI3K/Akt", 
      "MAPK/ERK", 
      "biological network analysis", 
      "serine/threonine protein kinase", 
      "constitutive activation", 
      "cancer cells", 
      "threonine protein kinase", 
      "MAPK/ERK pathway", 
      "signal-regulated kinase", 
      "HER2-positive cancer cells", 
      "human gastric cancer cells", 
      "cell cycle arrest", 
      "gastric cancer cells", 
      "phosphoproteomic data", 
      "human epidermal growth factor receptor-2 (HER2) tyrosine kinases", 
      "protein kinase", 
      "growth factor receptor", 
      "protein network", 
      "phosphopeptide enrichment methods", 
      "cancer cell resistance", 
      "hybrid quadrupole-orbitrap mass spectrometer", 
      "network analysis", 
      "tyrosine kinase", 
      "Exactive hybrid quadrupole-orbitrap mass spectrometer", 
      "ERK pathway", 
      "kinase", 
      "cycle arrest", 
      "cancer cell lines", 
      "parental cells", 
      "analysis identifies", 
      "factor receptor", 
      "pathway modulation", 
      "cell proliferation", 
      "resistance mechanisms", 
      "Akt", 
      "lapatinib sensitivity", 
      "cell lines", 
      "pathway activation", 
      "growth inhibitor", 
      "gastric cancer cell resistance", 
      "quadrupole-orbitrap mass spectrometer", 
      "pathway", 
      "enrichment method", 
      "ERK", 
      "cell resistance", 
      "cells", 
      "activation", 
      "dual inhibitor", 
      "systematic quantitative comparison", 
      "phosphoproteome", 
      "phosphoprotein", 
      "inhibitors", 
      "phosphatidylinositide", 
      "proliferation", 
      "arrest", 
      "receptors", 
      "resistance", 
      "lapatinib", 
      "inhibition", 
      "mechanism", 
      "major clinical challenge", 
      "analysis", 
      "lines", 
      "manner", 
      "modulation", 
      "identifies", 
      "agents", 
      "drug treatment", 
      "quantitative comparison", 
      "events", 
      "mass spectrometer", 
      "combination", 
      "findings", 
      "effect", 
      "sensitivity", 
      "data", 
      "drugs", 
      "comparison", 
      "results", 
      "treatment", 
      "clinical challenge", 
      "network", 
      "challenges", 
      "HER2-targeted agents", 
      "method", 
      "promising results", 
      "spectrometer"
    ], 
    "name": "Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line", 
    "pagination": "e64-e64", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025899051"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/emm.2013.115"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24263233"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/emm.2013.115", 
      "https://app.dimensions.ai/details/publication/pub.1025899051"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_606.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/emm.2013.115"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/emm.2013.115'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/emm.2013.115'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/emm.2013.115'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/emm.2013.115'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      21 PREDICATES      133 URIs      120 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/emm.2013.115 schema:about N0a278d2561e24f98bebf8dba272e53cd
2 N1551d8f3fbcc42858c82317c77dc4655
3 N2a72a92a96be4972aaa24ffc226503a7
4 N59666aa89a404df19eb780b22d37af16
5 N7ebc1560c99c496899adc062949289a7
6 N8533601dbb6b43e6b084251bbbe68ab1
7 N9721dcf9701d4759b0b4e73efc8caca0
8 N9c48ec612df244cc992e82e4bcd1d58d
9 Na2a103a909f64ec49ec243ddf3dc1191
10 Nc366e40b108f4661be498f71d589106d
11 Ndd1f453e566b41ea8ca21fd4b1f52870
12 Ne7d3f5531e074c6bb3adab52fffe0f7b
13 Neb0c4390a74343c897ca43d565e5a562
14 Ned7c21eb5000401f800e41fffc2dc30c
15 anzsrc-for:03
16 anzsrc-for:0304
17 schema:author Na10ca4b3fc9449c09876bc7235ffb68b
18 schema:citation sg:pub.10.1038/nbt1240
19 sg:pub.10.1038/ncponc1156
20 sg:pub.10.1038/onc.2011.130
21 sg:pub.10.1038/onc.2011.84
22 sg:pub.10.1038/sj.bjc.6604937
23 schema:datePublished 2013-11-22
24 schema:datePublishedReg 2013-11-22
25 schema:description Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro. However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge. To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer. Biological network analysis of differentially expressed phosphoproteins revealed apparent constitutive activation of the MET-axis phosphatidylinositide 3-kinase (PI3K)/α-serine/threonine-protein kinase (AKT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways in SNU216-LR. Inhibition of the PI3K/AKT and MAPK/ERK signaling pathways in SNU216-LR also leads to cell cycle arrest, confirming the biological network analysis. Lapatinib sensitivity was restored when cells were treated with several molecular targeting agents in combination with lapatinib. Thus, by integrating phosphoproteomic data, protein networks and effects of signaling pathway modulation on cell proliferation, we found that SNU216-LR maintains constitutive activation of the PI3K/AKT and MAPK/ERK pathways in a MET-dependent manner. These findings suggest that pathway activation is a key compensatory intracellular phospho-signaling event that may govern gastric cancer cell resistance to drug treatment.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N117b2f8b508041529e6853c63a6d8eaf
29 Ndeddf898d50c4b2480e2c7117a3a56b9
30 sg:journal.1085098
31 schema:keywords Akt
32 ERK
33 ERK pathway
34 Exactive hybrid quadrupole-orbitrap mass spectrometer
35 HER2-positive cancer cells
36 HER2-targeted agents
37 MAPK/ERK
38 MAPK/ERK pathway
39 PI3K/Akt
40 activation
41 agents
42 analysis
43 analysis identifies
44 arrest
45 biological network analysis
46 cancer cell lines
47 cancer cell resistance
48 cancer cells
49 cell cycle arrest
50 cell lines
51 cell proliferation
52 cell resistance
53 cells
54 challenges
55 clinical challenge
56 combination
57 comparison
58 constitutive activation
59 cycle arrest
60 data
61 drug treatment
62 drugs
63 dual inhibitor
64 effect
65 enrichment method
66 epidermal growth factor receptor
67 events
68 factor receptor
69 findings
70 gastric cancer cell resistance
71 gastric cancer cells
72 growth factor receptor
73 growth inhibitor
74 human epidermal growth factor receptor-2 (HER2) tyrosine kinases
75 human gastric cancer cells
76 hybrid quadrupole-orbitrap mass spectrometer
77 identifies
78 inhibition
79 inhibitors
80 kinase
81 lapatinib
82 lapatinib sensitivity
83 lines
84 major clinical challenge
85 manner
86 mass spectrometer
87 mechanism
88 method
89 mitogen-activated protein kinase
90 modulation
91 network
92 network analysis
93 parental cells
94 pathway
95 pathway activation
96 pathway modulation
97 phosphatidylinositide
98 phosphopeptide enrichment methods
99 phosphoprotein
100 phosphoproteome
101 phosphoproteomic data
102 proliferation
103 promising results
104 protein kinase
105 protein network
106 quadrupole-orbitrap mass spectrometer
107 quantitative comparison
108 receptors
109 resistance
110 resistance mechanisms
111 results
112 sensitivity
113 serine/threonine protein kinase
114 signal-regulated kinase
115 spectrometer
116 systematic quantitative comparison
117 threonine protein kinase
118 treatment
119 tyrosine kinase
120 schema:name Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line
121 schema:pagination e64-e64
122 schema:productId Na59a78ad87bd4fa5aee1fd04442aedfa
123 Nbd0eb399e19e4d2e8a0c1f0322ac9177
124 Nd24b1907a50c4ad18e0a48beb3a78ed0
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025899051
126 https://doi.org/10.1038/emm.2013.115
127 schema:sdDatePublished 2022-09-02T15:56
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher Nfce0d3e7a453494285a0528cea0b87bc
130 schema:url https://doi.org/10.1038/emm.2013.115
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N0a278d2561e24f98bebf8dba272e53cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Lapatinib
136 rdf:type schema:DefinedTerm
137 N117b2f8b508041529e6853c63a6d8eaf schema:volumeNumber 45
138 rdf:type schema:PublicationVolume
139 N1551d8f3fbcc42858c82317c77dc4655 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Antineoplastic Agents
141 rdf:type schema:DefinedTerm
142 N29a7f25764434cdc83f284ea8832c81d rdf:first sg:person.01064603366.33
143 rdf:rest rdf:nil
144 N2a72a92a96be4972aaa24ffc226503a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Cell Line, Tumor
146 rdf:type schema:DefinedTerm
147 N3dea555a3f914c72b1844cc703831ac7 rdf:first sg:person.012010335604.34
148 rdf:rest N29a7f25764434cdc83f284ea8832c81d
149 N5020d794445142cd85444c6c9ce18fb4 rdf:first sg:person.0626600563.08
150 rdf:rest N3dea555a3f914c72b1844cc703831ac7
151 N59666aa89a404df19eb780b22d37af16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Drug Resistance, Neoplasm
153 rdf:type schema:DefinedTerm
154 N7ebc1560c99c496899adc062949289a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Proteomics
156 rdf:type schema:DefinedTerm
157 N8533601dbb6b43e6b084251bbbe68ab1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Phosphorylation
159 rdf:type schema:DefinedTerm
160 N9721dcf9701d4759b0b4e73efc8caca0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Phosphatidylinositol 3-Kinases
162 rdf:type schema:DefinedTerm
163 N9c48ec612df244cc992e82e4bcd1d58d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Quinazolines
165 rdf:type schema:DefinedTerm
166 N9d854c4decbd4201b787b171a2e97857 rdf:first sg:person.01170702676.14
167 rdf:rest Nb072118c8b1945928ba6e466cf0c8fa2
168 Na10ca4b3fc9449c09876bc7235ffb68b rdf:first sg:person.01007741370.54
169 rdf:rest Nf37fc8f2b77b4136969e94e796b06947
170 Na2a103a909f64ec49ec243ddf3dc1191 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Proto-Oncogene Proteins c-akt
172 rdf:type schema:DefinedTerm
173 Na59a78ad87bd4fa5aee1fd04442aedfa schema:name dimensions_id
174 schema:value pub.1025899051
175 rdf:type schema:PropertyValue
176 Nb072118c8b1945928ba6e466cf0c8fa2 rdf:first sg:person.0726657204.24
177 rdf:rest N5020d794445142cd85444c6c9ce18fb4
178 Nbd0eb399e19e4d2e8a0c1f0322ac9177 schema:name doi
179 schema:value 10.1038/emm.2013.115
180 rdf:type schema:PropertyValue
181 Nc366e40b108f4661be498f71d589106d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Mitogen-Activated Protein Kinase Kinases
183 rdf:type schema:DefinedTerm
184 Nd24b1907a50c4ad18e0a48beb3a78ed0 schema:name pubmed_id
185 schema:value 24263233
186 rdf:type schema:PropertyValue
187 Ndd1f453e566b41ea8ca21fd4b1f52870 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name MAP Kinase Signaling System
189 rdf:type schema:DefinedTerm
190 Ndeddf898d50c4b2480e2c7117a3a56b9 schema:issueNumber 11
191 rdf:type schema:PublicationIssue
192 Ne7d3f5531e074c6bb3adab52fffe0f7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Humans
194 rdf:type schema:DefinedTerm
195 Neb0c4390a74343c897ca43d565e5a562 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Proto-Oncogene Proteins c-met
197 rdf:type schema:DefinedTerm
198 Ned7c21eb5000401f800e41fffc2dc30c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Mitogen-Activated Protein Kinases
200 rdf:type schema:DefinedTerm
201 Nf37fc8f2b77b4136969e94e796b06947 rdf:first sg:person.01061620023.23
202 rdf:rest N9d854c4decbd4201b787b171a2e97857
203 Nfce0d3e7a453494285a0528cea0b87bc schema:name Springer Nature - SN SciGraph project
204 rdf:type schema:Organization
205 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
206 schema:name Chemical Sciences
207 rdf:type schema:DefinedTerm
208 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medicinal and Biomolecular Chemistry
210 rdf:type schema:DefinedTerm
211 sg:journal.1085098 schema:issn 1226-3613
212 2092-6413
213 schema:name Experimental & Molecular Medicine
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01007741370.54 schema:affiliation grid-institutes:grid.31501.36
217 schema:familyName Lee
218 schema:givenName Yong Yook
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007741370.54
220 rdf:type schema:Person
221 sg:person.01061620023.23 schema:affiliation grid-institutes:grid.31501.36
222 schema:familyName Kim
223 schema:givenName Hwang-Phill
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061620023.23
225 rdf:type schema:Person
226 sg:person.01064603366.33 schema:affiliation grid-institutes:grid.31501.36
227 schema:familyName Yi
228 schema:givenName Eugene C
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064603366.33
230 rdf:type schema:Person
231 sg:person.01170702676.14 schema:affiliation grid-institutes:grid.31501.36
232 schema:familyName Kang
233 schema:givenName Min Jueng
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170702676.14
235 rdf:type schema:Person
236 sg:person.012010335604.34 schema:affiliation grid-institutes:grid.31501.36
237 schema:familyName Kim
238 schema:givenName Tae-You
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012010335604.34
240 rdf:type schema:Person
241 sg:person.0626600563.08 schema:affiliation grid-institutes:grid.31501.36
242 schema:familyName Han
243 schema:givenName Sae-Won
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626600563.08
245 rdf:type schema:Person
246 sg:person.0726657204.24 schema:affiliation grid-institutes:grid.31501.36
247 schema:familyName Cho
248 schema:givenName Byoung-Kyu
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726657204.24
250 rdf:type schema:Person
251 sg:pub.10.1038/nbt1240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011188595
252 https://doi.org/10.1038/nbt1240
253 rdf:type schema:CreativeWork
254 sg:pub.10.1038/ncponc1156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031325623
255 https://doi.org/10.1038/ncponc1156
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/onc.2011.130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047704859
258 https://doi.org/10.1038/onc.2011.130
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/onc.2011.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017010571
261 https://doi.org/10.1038/onc.2011.84
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/sj.bjc.6604937 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051636968
264 https://doi.org/10.1038/sj.bjc.6604937
265 rdf:type schema:CreativeWork
266 grid-institutes:grid.31501.36 schema:alternateName Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
267 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
268 WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea
269 Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea
270 schema:name Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
271 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
272 WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea
273 Wide River Institute of Immunology, Seoul National University, Seoul, Republic of Korea
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...